Update on status of Foreign Medical Students
Foreign Medical Students/Graduates are either covered under “Screening Test Regulations, 2002” or “Foreign Medical Graduate Licentiate Regulations, 2021”. There are no such provisions in the Indian Medical Council Act 1956 & the National Medical Commission Act, 2019 as well as the Regulations to accommodate or transfer medical students from any foreign medical institutes to Indian […]
Pharmaceutical Technology Upgradation Assistance Scheme for MSMEs
MSMEs have availed the benefit under erstwhile PTUAS scheme. However, the PTUAS has been incorporated as a sub-scheme under the Scheme - Strengthening of Pharmaceutical Industry (SPI), which was launched in July 2022. The Strengthening of Pharmaceutical Industry (SPI), with the financial outlay of Rs. 500 crores and with a tenure from FY 2021-2022 to […]
Update on National Family Planning Program
The Government accords top priority to the National Family Planning Program, which is guided by the tenets of the National Population Policy 2000 and National Health Policy 2017, to address the unmet need for Family Planning. The following steps have been taken by the Government: Expanded Contraceptive Choices Mission Parivar Vikas (MPV) implemented in 13 […]
Update on MBBS & PG seats in Indian Medical Colleges
A total of 96,077 MBBS seats are available in the country out of which 51,712 in Government Medical Colleges and 44365 in Private Medical Colleges. There are 49,790 PG seats of National Medical Commission (NMC) available in the country, out of which 30,384 in Government Medical Colleges and 19,406 in Private Medical Colleges. There are […]
Guidelines for prescribing generic medicines in public hospitals
The Government has put in place a Uniform Code for Pharmaceutical Marketing Practices (UCPMP) for Pharmaceutical companies, which is in operation since 01.01.2015, to prevent unethical practices by the pharmaceutical companies. This code governs the conduct of pharmaceutical companies in their marketing practices, duly covering the various aspects such as medical representatives, textual and audio-visual […]
LSW LifeScienceWorld lost one of its initial Advisory Board Members and a well-wisher on the 6th December, 2022
LSWLifeScienceWorld lost one of its initial Advisory Board Members and a well-wisher on the 6th December, 2022. Dr. S G A Rao, was our guide and always gave valuable suggestions on the editorial front and contributed articles in the stem cell area which was his specialisation. He conceived the entire program of our interactive meeting […]
WHO and football icons rally to score a goal for “Health for All” to build healthier future
12 December 2022 I Geneva and Doha -- On Universal Health Coverage Day (UHC Day), the World Health Organization (WHO) teams up with international football icons to urge action by governments and people across the world to achieve health for all. UHC ensures that everyone, everywhere can access the support they need to be and […]
Roche presents new data demonstrating the potential benefit of glofitamab and Lunsumio as fixed-duration, off-the-shelf treatment options for lymphoma
Data showcase the potential of glofitamab and Lunsumio to address diverse patient needs. Data presented at ASH 2022 and simultaneously published in the New England Journal of Medicine showed that glofitamab, given as a fixed course, induced early and durable responses in people with heavily pre-treated large B-cell lymphoma. 27-month follow-up data showed Lunsumio continued […]
Roche’s subcutaneous crovalimab given every four weeks achieves disease control in people with PNH, a life-threatening blood condition
The phase III COMMODORE 3 study of crovalimab met primary endpoints of transfusion avoidance and haemolysis control in people with paroxysmal nocturnal hemoglobinuria (PNH). COMMODORE 3 is the first China-specific study in PNH. Current treatment options are extremely limited in China, resulting in significant levels of disease-related morbidity and mortality for people living with PNH. […]
Interim data from phase III study presented at ASH 2022 show Hemlibra achieved meaningful bleed control in infants from birth
The HAVEN 7 study was designed to further confirm the benefit of preventative treatment (prophylaxis) with Hemlibra from birth in previously untreated or minimally treated infants with severe haemophilia A without inhibitors. In the study, 77.8% of participants had no bleeding episodes that required treatment. In addition, real-world efficacy and safety data from the EUHASS […]
